JP2009522239A - トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 - Google Patents
トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 Download PDFInfo
- Publication number
- JP2009522239A JP2009522239A JP2008547980A JP2008547980A JP2009522239A JP 2009522239 A JP2009522239 A JP 2009522239A JP 2008547980 A JP2008547980 A JP 2008547980A JP 2008547980 A JP2008547980 A JP 2008547980A JP 2009522239 A JP2009522239 A JP 2009522239A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- unsubstituted
- substituted
- independently hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Triterpene quinones Chemical class 0.000 title claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 15
- 208000030852 Parasitic disease Diseases 0.000 title claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 239000000651 prodrug Substances 0.000 claims abstract description 25
- 229940002612 prodrug Drugs 0.000 claims abstract description 25
- 239000012453 solvate Substances 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 795
- 239000001257 hydrogen Substances 0.000 claims description 795
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 678
- 125000000217 alkyl group Chemical group 0.000 claims description 501
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 362
- 125000003118 aryl group Chemical group 0.000 claims description 323
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 307
- 150000001875 compounds Chemical class 0.000 claims description 211
- 229910052736 halogen Inorganic materials 0.000 claims description 186
- 150000002367 halogens Chemical class 0.000 claims description 186
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 182
- 229910052799 carbon Inorganic materials 0.000 claims description 147
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 144
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 143
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 131
- 125000003277 amino group Chemical group 0.000 claims description 102
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 77
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 47
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 150000002431 hydrogen Chemical class 0.000 claims description 39
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 24
- 230000001404 mediated effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- HDIIUCVOZICRAQ-UHFFFAOYSA-N methyl 3,10-dihydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)O)(C)C(=O)OC)C)(C)C3=CC=C21 HDIIUCVOZICRAQ-UHFFFAOYSA-N 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- QIRUFAFQGKOTKA-UHFFFAOYSA-N 3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(C(O)C4(CCC33C)C)=O)C)C)(C)C3=CC=C21 QIRUFAFQGKOTKA-UHFFFAOYSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- ZADMHKPVSIUMDA-UHFFFAOYSA-N (9-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl) acetate Chemical compound CC1=C(OC(C)=O)C(=O)C=C2C(CCC3(C4CC(C(C(O)C4(CCC33C)C)=O)C)C)(C)C3=CC=C21 ZADMHKPVSIUMDA-UHFFFAOYSA-N 0.000 claims description 9
- YQUDHIFSNVKFLU-UHFFFAOYSA-N (9-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl) dodecanoate Chemical compound C1C(C)C(=O)C(O)C2(C)CCC3(C)C4=CC=C5C(C)=C(OC(=O)CCCCCCCCCCC)C(=O)C=C5C4(C)CCC3(C)C21 YQUDHIFSNVKFLU-UHFFFAOYSA-N 0.000 claims description 9
- KQJSQWZMSAGSHN-UHFFFAOYSA-N 10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid Chemical compound CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims description 9
- WSTYNZDAOAEEKG-UHFFFAOYSA-N 3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 claims description 9
- GGXFXLUYODZCPP-UHFFFAOYSA-N CC1CC2C(C)(CC(O)C3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)C(Br)CC23C)C(O)C1=O Chemical compound CC1CC2C(C)(CC(O)C3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)C(Br)CC23C)C(O)C1=O GGXFXLUYODZCPP-UHFFFAOYSA-N 0.000 claims description 9
- VYNHXIVBGQAGPG-UHFFFAOYSA-N CC1CC2C(C)(CCC3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)C(Br)CC23C)CC1=O Chemical compound CC1CC2C(C)(CCC3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)C(Br)CC23C)CC1=O VYNHXIVBGQAGPG-UHFFFAOYSA-N 0.000 claims description 9
- SKPHMRFPHWROCY-UHFFFAOYSA-N OC1=C(C2=CC=C3C4(CCC5(C(C(C(CC5C4(CCC3(C2=CC1=O)C)C)C)=O)OC(CCC(=O)O)=O)C)C)C Chemical compound OC1=C(C2=CC=C3C4(CCC5(C(C(C(CC5C4(CCC3(C2=CC1=O)C)C)C)=O)OC(CCC(=O)O)=O)C)C)C SKPHMRFPHWROCY-UHFFFAOYSA-N 0.000 claims description 9
- JFACETXYABVHFD-UHFFFAOYSA-N primisterin Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 claims description 9
- LOLKAJARZKDJTD-UHFFFAOYSA-N 4-Ethoxy-4-oxobutanoic acid Chemical compound CCOC(=O)CCC(O)=O LOLKAJARZKDJTD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- XGZWQILSPYWGJA-UHFFFAOYSA-N (9-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl) n,n-dimethylcarbamate Chemical compound CC1=C(OC(=O)N(C)C)C(=O)C=C2C(CCC3(C4CC(C(C(O)C4(CCC33C)C)=O)C)C)(C)C3=CC=C21 XGZWQILSPYWGJA-UHFFFAOYSA-N 0.000 claims description 7
- DIXKVSUALBFPHK-UHFFFAOYSA-N (9-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl) pyridine-3-carboxylate Chemical compound OC1C(=O)C(C)CC(C2(CCC3(C)C4=CC5=O)C)C1(C)CCC2(C)C3=CC=C4C(C)=C5OC(=O)C1=CC=CN=C1 DIXKVSUALBFPHK-UHFFFAOYSA-N 0.000 claims description 7
- BCHDKANHNVHEMT-UHFFFAOYSA-N methyl 10-(dimethylcarbamoyloxy)-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound CC1=C(OC(=O)N(C)C)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 BCHDKANHNVHEMT-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- JLEXIDDAUDXLOA-UHFFFAOYSA-N 10,11-dihydroxy-2,4a,6a,9,14a-pentamethyl-1,2,4,5,6,13,14,14b-octahydropicen-3-one Chemical compound CC1=C(O)C(O)=CC2=C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)C3=CC=C21 JLEXIDDAUDXLOA-UHFFFAOYSA-N 0.000 claims description 6
- ZUBJJQDAWBBCMZ-UHFFFAOYSA-N 3,7,9-trihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(C(O)C4(CC(O)C33C)C)=O)C)C)(C)C3=CC=C21 ZUBJJQDAWBBCMZ-UHFFFAOYSA-N 0.000 claims description 6
- HEQXBZZPYWEMJC-UHFFFAOYSA-N CC1CC2C(C)(CCC3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)CCC23C)CC1O Chemical compound CC1CC2C(C)(CCC3(C)C4=CC=C5C(C)=C(O)C(=O)C=C5C4(C)CCC23C)CC1O HEQXBZZPYWEMJC-UHFFFAOYSA-N 0.000 claims description 6
- DNBZTECFUWBMRA-UHFFFAOYSA-N methyl 2,4a,6a,6a,9,14a-hexamethyl-11-oxo-10-propanoyloxy-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound C1C(C)(C(=O)OC)CCC2(C)CCC3(C)C4=CC=C5C(C)=C(OC(=O)CC)C(=O)C=C5C4(C)CCC3(C)C21 DNBZTECFUWBMRA-UHFFFAOYSA-N 0.000 claims description 6
- WLNFKDMGLUPVAE-UHFFFAOYSA-N methyl 7,10,11-trihydroxy-2,4a,6a,6a,9,14a-hexamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound OC1=C(O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=C(O)C(=O)C2=C1C WLNFKDMGLUPVAE-UHFFFAOYSA-N 0.000 claims description 6
- HFOZJSCLBUTFCX-UHFFFAOYSA-N methyl 9-formyl-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound OC1=C(O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC(=O)C2=C1C=O HFOZJSCLBUTFCX-UHFFFAOYSA-N 0.000 claims description 6
- ZHAQHYYKWKPTLK-UHFFFAOYSA-N 10,11-dihydroxy-2,4a,6a,9,14a-pentamethyl-4,5,6,13,14,14b-hexahydropicen-3-one Chemical compound CC1=C(O)C(O)=CC2=C(CCC3(C4C=C(C(CC4(CCC33C)C)=O)C)C)C3=CC=C21 ZHAQHYYKWKPTLK-UHFFFAOYSA-N 0.000 claims description 5
- ISVNJMOKAIZZAO-UHFFFAOYSA-N CCOC(=O)CCC(=O)OC1C(=O)C(C)CC2C1(C)CCC1(C)C3=CC=C4C(C)=C(O)C(=O)C=C4C3(C)CCC21C Chemical compound CCOC(=O)CCC(=O)OC1C(=O)C(C)CC2C1(C)CCC1(C)C3=CC=C4C(C)=C(O)C(=O)C=C4C3(C)CCC21C ISVNJMOKAIZZAO-UHFFFAOYSA-N 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- IGVNLMJNJQFUKS-UHFFFAOYSA-N methyl 11-hydroxy-10-(2-methoxyethoxymethoxy)-2,4a,6a,6a,9,14a-hexamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate Chemical compound C1C(C)(C(=O)OC)CCC2(C)CCC3(C)C4=CC(=O)C5=C(C)C(OCOCCOC)=C(O)C=C5C4(C)CCC3(C)C21 IGVNLMJNJQFUKS-UHFFFAOYSA-N 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 241000223104 Trypanosoma Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- IXPYLALKHKSDKR-UHFFFAOYSA-N 1,9-dihydropicene-2,10-dione Chemical compound C1C(=O)C=CC2=CC=C3C4=CC=C5CC(=O)C=CC5=C4C=CC3=C21 IXPYLALKHKSDKR-UHFFFAOYSA-N 0.000 claims description 2
- YTTSTILQZWUCRJ-UHFFFAOYSA-N 3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydro-7h-picen-2-one Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)C)(C)C4=CC=C21 YTTSTILQZWUCRJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000224016 Plasmodium Species 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- IRJPBHRNBANDAC-UHFFFAOYSA-N 10,11-dihydroxy-2,4a,6a,9,14a-pentamethyl-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid Chemical compound OC1=C(C2=CC=C3C4(CCC5(CCC(CC5C4(CCC3=C2C=C1O)C)(C(=O)O)C)C)C)C IRJPBHRNBANDAC-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 102000002745 Choline Kinase Human genes 0.000 abstract description 35
- 108010018888 Choline kinase Proteins 0.000 abstract description 35
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 4
- 241000233866 Fungi Species 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 4
- 150000003648 triterpenes Chemical class 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 0 C[C@](*)([C@@]1(C)*)[C@]2(C)C(C=C[C@]3(C)[C@]4(C)CC[C@@](CCCC5)C3C[C@]5(C)C(OC)=O)=C4C=CC2=C(C)[C@]1(C)*#C Chemical compound C[C@](*)([C@@]1(C)*)[C@]2(C)C(C=C[C@]3(C)[C@]4(C)CC[C@@](CCCC5)C3C[C@]5(C)C(OC)=O)=C4C=CC2=C(C)[C@]1(C)*#C 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229950004354 phosphorylcholine Drugs 0.000 description 9
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- VKPJRDFHXPLERI-UHFFFAOYSA-N (4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl) acetate Chemical compound CC1=C(OC(C)=O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 VKPJRDFHXPLERI-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- WTJTYAFIQLZLHS-UHFFFAOYSA-N 3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,12a,13,14-hexahydropicene-2,10-dione Chemical compound CC1=C(O)C(=O)C=C2C(CCC3(C4C=C(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WTJTYAFIQLZLHS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QIRUFAFQGKOTKA-ZRWKYKNNSA-N (6as,6bs,8ar,9s,11r,12as,14ar)-3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3([C@@H]4C[C@H](C([C@@H](O)[C@@]4(CC[C@@]33C)C)=O)C)C)(C)C3=CC=C21 QIRUFAFQGKOTKA-ZRWKYKNNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- WSTYNZDAOAEEKG-QSPBTJQRSA-N Maytenin Natural products CC1=C(O)C(=O)C=C2[C@@](CC[C@@]3([C@@H]4C[C@H](C(C[C@@]4(CC[C@]33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-QSPBTJQRSA-N 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- WSTYNZDAOAEEKG-GWJSGULQSA-N tingenone Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3([C@@H]4C[C@H](C(C[C@@]4(CC[C@@]33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-GWJSGULQSA-N 0.000 description 3
- XLSRVRBFPQIONB-UHFFFAOYSA-N tingenone Natural products CC1CC2C(C)(CCC3(C)C4=CC=C5C=C(O)C(=O)C=C5C4(C)CCC23C)CC1=O XLSRVRBFPQIONB-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PYCHVJVRDAIMEF-UHFFFAOYSA-N 2-(4,6a,6b,8a,11,14a-hexamethyl-2,10-dioxo-7,8,9,11,12,12a,13,14-octahydropicen-3-yl)acetic acid Chemical compound CC1=C(C(C=C2C3(CCC4(C5CC(C(CC5(CCC4(C3=CC=C12)C)C)=O)C)C)C)=O)CC(=O)O PYCHVJVRDAIMEF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000549168 Maytenus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 description 1
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 241000545263 Salacia <hydroid> Species 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- MSIGGUSMCUUDGY-LGUBBEMLSA-M [Cl-].CO[14CH2]C[N+](C)(C)C Chemical compound [Cl-].CO[14CH2]C[N+](C)(C)C MSIGGUSMCUUDGY-LGUBBEMLSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- KVSNMTUIMXZPLU-XOZXFAFYSA-N friedelane Chemical class C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC[C@@H]1C KVSNMTUIMXZPLU-XOZXFAFYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
- C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200503263A ES2277568B1 (es) | 2005-12-30 | 2005-12-30 | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
PCT/EP2006/070276 WO2007077203A2 (fr) | 2005-12-30 | 2006-12-29 | Derives de triterpenequinone et de triterpenephenol et leur application pour le traitement de tumeurs et de maladies parasitaires |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009522239A true JP2009522239A (ja) | 2009-06-11 |
Family
ID=37946257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008547980A Pending JP2009522239A (ja) | 2005-12-30 | 2006-12-29 | トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1976533A2 (fr) |
JP (1) | JP2009522239A (fr) |
KR (1) | KR20080083044A (fr) |
CN (1) | CN101351211A (fr) |
AU (1) | AU2006334359A1 (fr) |
BR (1) | BRPI0620845A2 (fr) |
CA (1) | CA2635318A1 (fr) |
ES (1) | ES2277568B1 (fr) |
MX (1) | MX2008008556A (fr) |
RU (1) | RU2008131311A (fr) |
WO (1) | WO2007077203A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101405403B (zh) | 2005-04-13 | 2013-07-10 | 科学研究高等机关 | 鉴定用于癌症治疗的化合物的体外方法 |
WO2009026163A1 (fr) * | 2007-08-17 | 2009-02-26 | Burnham Institute For Medical Research | Compositions et procédés pour inhiber la croissance et la métastase d'un mélanome |
CN101434635B (zh) * | 2007-11-16 | 2012-05-16 | 上海华拓医药科技发展股份有限公司 | 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法 |
US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
WO2010049173A1 (fr) * | 2008-10-31 | 2010-05-06 | Cenix Bioscience Gmbh | Utilisation d’inhibiteurs de kinases hôtes pour traiter les maladies infectieuses |
CA2808359C (fr) * | 2010-08-23 | 2019-09-24 | Suzhou Neupharma Co., Ltd. | Analogues de celasterol et compositions pharmaceutiques en renfermant |
BR112018008103A2 (pt) | 2015-10-23 | 2018-11-06 | Erx Pharmaceuticals, Inc. | análogos de celastrol |
EP3480207A4 (fr) * | 2016-07-04 | 2020-03-11 | Xiamen University | Ligand de récepteur nucléaire orphelin nur77 et son application |
ES2899114T3 (es) | 2016-07-25 | 2022-03-10 | Nerviano Medical Sciences Srl | Análogos de purina y 3-deazapurina como inhibidores de colina cinasa |
US11117901B2 (en) | 2017-07-11 | 2021-09-14 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors |
WO2020257658A1 (fr) | 2019-06-20 | 2020-12-24 | University Of Iowa Research Foundation | Nanoparticules comprenant des quinone-méthides et compositions à utiliser |
CN113827599A (zh) * | 2021-09-23 | 2021-12-24 | 天津国际生物医药联合研究院 | 去甲泽拉木醛在抗登革病毒感染中的潜在应用 |
CN116023426A (zh) * | 2022-12-30 | 2023-04-28 | 上海海洋大学 | 去甲泽拉木醛衍生物及其在制备抗癌药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328309A (en) * | 1980-07-02 | 1982-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Method for producing tripdiolide, triptolide and celastrol |
DE4117854A1 (de) * | 1991-05-31 | 1992-12-03 | Wiemann Wolfram | Verwendung mindestens eines celastroloids als bestandteil fuer ein arzneimittel zur behandlung von erkrankungen des rheumatoiden formenkreises, insbesondere rheumatismus |
US5650167A (en) * | 1995-11-16 | 1997-07-22 | Dawa Incorporated | Method and composition for treating hepatitis B |
ES2117950B1 (es) | 1996-08-02 | 1999-09-16 | Univ Granada | Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular. |
CN1155610C (zh) * | 2002-11-05 | 2004-06-30 | 浙江大学 | 具有抗氧化和抗肿瘤活性扁蒴藤素系列衍生物及合成方法 |
US20040220267A1 (en) * | 2003-02-07 | 2004-11-04 | Devlin J. P. | Derivatives of pentacyclic nortriterpene quinone methides as compounds useful in the treatment of inflammatory, neurodegenerative, and neoplastic diseases |
-
2005
- 2005-12-30 ES ES200503263A patent/ES2277568B1/es not_active Expired - Fee Related
-
2006
- 2006-12-29 WO PCT/EP2006/070276 patent/WO2007077203A2/fr active Application Filing
- 2006-12-29 MX MX2008008556A patent/MX2008008556A/es unknown
- 2006-12-29 CN CNA2006800499371A patent/CN101351211A/zh active Pending
- 2006-12-29 JP JP2008547980A patent/JP2009522239A/ja active Pending
- 2006-12-29 CA CA002635318A patent/CA2635318A1/fr not_active Abandoned
- 2006-12-29 KR KR1020087018837A patent/KR20080083044A/ko not_active Application Discontinuation
- 2006-12-29 BR BRPI0620845-2A patent/BRPI0620845A2/pt not_active Application Discontinuation
- 2006-12-29 AU AU2006334359A patent/AU2006334359A1/en not_active Abandoned
- 2006-12-29 RU RU2008131311/04A patent/RU2008131311A/ru not_active Application Discontinuation
- 2006-12-29 EP EP06830856A patent/EP1976533A2/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2277568B1 (es) | 2008-04-01 |
RU2008131311A (ru) | 2010-02-10 |
CN101351211A (zh) | 2009-01-21 |
WO2007077203A3 (fr) | 2007-08-30 |
KR20080083044A (ko) | 2008-09-12 |
BRPI0620845A2 (pt) | 2011-11-22 |
CA2635318A1 (fr) | 2007-07-12 |
AU2006334359A1 (en) | 2007-07-12 |
MX2008008556A (es) | 2008-09-26 |
WO2007077203A2 (fr) | 2007-07-12 |
EP1976533A2 (fr) | 2008-10-08 |
AU2006334359A2 (en) | 2008-08-07 |
ES2277568A1 (es) | 2007-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009522239A (ja) | トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 | |
Tan et al. | Synthesis, DNA binding and cytotoxicity of new pyrazole emodin derivatives | |
US20060234956A1 (en) | Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof | |
Chien et al. | Secondary metabolites from the root of Ehretia longiflora and their biological activities | |
Li et al. | Synthesis, antitumor activity evaluation and mechanistic study of novel hederacolchiside A1 derivatives bearing an aryl triazole moiety | |
JP4425109B2 (ja) | 腫瘍/癌細胞の増殖の抑制活性を有するガンボージ樹脂から単離した化合物及びその化合物を含む薬学的組成物 | |
JP2017048195A (ja) | ガンおよび他の疾患を治療するための新規化合物 | |
Ma et al. | Synthesis and anti-cancer activity studies of dammarane-type triterpenoid derivatives | |
JP3285361B2 (ja) | コルヒチン骨格化合物、それらの医薬としての用途、及びそれらを含有する組成物 | |
Ulusoy et al. | Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction | |
WO2023125928A1 (fr) | Inhibiteur de ménine et son utilisation | |
Zhu et al. | Design and synthesis of NAD (P) H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties | |
Kang et al. | Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia | |
Munikishore et al. | Structurally modified Cyclovirobuxine-D Buxus alkaloids as effective analgesic agents through Cav3. 2 T-Type calcium channel inhibition | |
Liu et al. | Dihydromyricetin from Ampelopsis grossedentata and its derivatives: Structural characterization and anti-hepatocellular carcinoma activity | |
Zhang et al. | A pair of new tirucallane triterpenoid epimers from the stems of Picrasma quassioides | |
CN109651377B (zh) | 一种治疗癌症的化合物及其用途 | |
JP2009274956A (ja) | ニーム種子由来の悪性腫瘍治療薬 | |
CN110698443A (zh) | 一种shp2小分子选择性抑制剂及其在制备抗肺癌药物中的应用 | |
CZ282473B6 (cs) | Bis(fenyl)ethanové deriváty, způsob jejich přípravy a farmaceutická kompozice tyto deriváty obsahující | |
Zhang et al. | Prunolactones AG, proangiogenic isocoumarin derivatives with an unusual 6/6/6/6/6 spiropentacyclic skeleton from the endophytic fungus Phomopsis prunorum | |
US9175030B2 (en) | Derivatives of avicin D and methods of making and using thereof | |
Sun et al. | Polycyclic polyprenylated acylphloroglucinol derivatives from Hypericum pseudohenryi | |
TWI227238B (en) | Novel pyranocoumarin compounds and their applications | |
Wang et al. | (±)-Yanhusuomide A, a pair of ornithine-fused benzylisoquinoline enantiomers from Corydalis yanhusuo |